Stay updated on Nivolumab and BMS986205 in Head&Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and BMS986205 in Head&Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and BMS986205 in Head&Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the study details related to the impact of IDO1 inhibitor BMS-986205 and nivolumab on tumor radiographic response in patients with squamous cell cancer of the head and neck.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:30.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail for clinical research participation.
    Difference
    41%
    Check dated 2024-05-22T20:59:18.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:46:38.000Z thumbnail image

Stay in the know with updates to Nivolumab and BMS986205 in Head&Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and BMS986205 in Head&Neck Cancer Clinical Trial page.